Current Management of CINV

Abstract

Chemotherapy-induced nausea and vomiting (CINV) prevention is important to reduce overall morbidity and financial burden in patients receiving chemotherapy. Severe symptoms reduce the patient's quality of life and can interfere with further treatment. The five major forms of CINV (ie, acute, delayed, predicted, breakthrough, and refractory) often include 5-HT3 receptor antagonists, NK1 receptor antagonists, and various treatments that often include corticosteroids. Despite significant research and development efforts on antiemetics, treatment of CINV remains a major challenge, waiting for many needs to be adequately addressed, including those that are vulnerable to CINV despite adequately treated. This review hope to raise awareness and discuss current current CINV management.